Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia

References

• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra1406184
   PubMed Web of Science ®Google Scholar
• Christian S, Arain S, Patel P, et al. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020;95(8):937–943. doi:10.1002/ajh.25838
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Patel S, Ho M, et al. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Am J Hematol. 2010;85(11):877–881. doi:10.1002/ajh.21857
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Martínez-Cuadrón D, Sanz M, et al. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018;97(7):1115–1153. doi:10.1007/s00277-018-3304-y
   PubMed Web of Science ®Google Scholar
• Park H, Youk J, Kim I, et al. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. Ann Hematol. 2016;95(11):1777–1786. doi:10.1007/s00277-016-2774-z
   PubMed Web of Science ®Google Scholar
• Price SL, Lancet JE, George TJ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011;35(3):301–304. doi:10.1016/j.leukres.2010.09.002
   PubMed Web of Science ®Google Scholar
• Scheckel CJ, Meyer M, Betcher JA, et al. Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo clinic cancer center: analysis of survival after ‘CLAG-M’ vs. ‘MEC. Leuk Res. 2020;90:106300. doi:10.1016/j.leukres.2020.106300
   PubMed Web of Science ®Google Scholar
• Stommel JM, Marchenko ND, Jimenez GS, et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. Embo J. 1999;18(6):1660–1672. doi:10.1093/emboj/18.6.1660
   PubMed Web of Science ®Google Scholar
• Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15(26):2648–2655. doi:10.2174/092986708786242859
   PubMed Web of Science ®Google Scholar
• Siddiqui N, Borden KL. mRNA export and cancer. Wiley Interdiscip Rev RNA. 2012;3(1):13–25. doi:10.1002/wrna.101
   PubMed Web of Science ®Google Scholar
• Etchin J, Sun Q, Kentsis A, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia. 2013;27(1):66–74. doi:10.1038/leu.2012.219
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621–4634. doi:10.1182/blood-2012-05-429506
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9):1765–1773. doi:10.1182/blood-2012-04-423160
   PubMed Web of Science ®Google Scholar
• Walker CJ, Oaks JJ, Santhanam R, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias. Blood. 2013;122(17):3034–3044. doi:10.1182/blood-2013-04-495374
   PubMed Web of Science ®Google Scholar
• Kojima K, Kornblau SM, Ruvolo V, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121(20):4166–4174. doi:10.1182/blood-2012-08-447581
   PubMed Web of Science ®Google Scholar
• Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24):3165–3174. doi:10.1182/blood-2016-11-750158
   PubMed Web of Science ®Google Scholar
• Bhatnagar B, Zhao Q, Mims AS, et al. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma. 2020;61(2):387–396. doi:10.1080/10428194.2019.1665664
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Kashyap T, Yu X, et al. XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase IIα to the nucleus. Clin Cancer Res. 2016;22(24):6142–6152. doi:10.1158/1078-0432.CCR-15-2885
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649. doi:10.1200/JCO.2003.04.036
   PubMed Web of Science ®Google Scholar
• Bader JC, Abdul Razak AR, Shacham S, et al. Pharmacokinetics of selinexor: the first-in-class selective inhibitor of nuclear export. Clin Pharmacokinet. 2021;60(8):957–969. doi:10.1007/s40262-021-01016-y
   PubMed Web of Science ®Google Scholar
• Marconi G, Talami A, Abbenante MC, et al. Mitoxantrone, etoposide and cytarabine (MEC) can induce deep complete remission and is an effective bridge therapy to allotransplantation (SCT) in refractory/relapsed acute myeloid leukemia (AML) patients. Blood. 2018;132(Supplement 1):4036–4036. doi:10.1182/blood-2018-99-113036
   Google Scholar
• Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004;22(6):1078–1086. doi:10.1200/JCO.2004.07.048
   PubMed Web of Science ®Google Scholar
• Fiedler W, Heuser M, Chromik J, et al. Phase II results of Ara-C and idarubicin in combination with the selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML. Blood. 2016;128(22):341–341. doi:10.1182/blood.V128.22.341.341
   Web of Science ®Google Scholar
• Abboud R, Chendamarai E, Rettig MP, et al. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2020;105(8):e404–e407. doi:10.3324/haematol.2019.236810
   PubMed Web of Science ®Google Scholar
• Martínez Sánchez MP, Megías-Vericat JE, Rodríguez-Veiga R, et al. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. Ann Hematol. 2021;100(6):1497–1508. doi:10.1007/s00277-021-04542-8
   PubMed Web of Science ®Google Scholar